2025-04-05 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Review

**0. Executive Summary:**

Johnson & Johnson (JNJ), a leading healthcare company, has underperformed the S&P 500 (VOO) significantly over the observed period. While exhibiting relatively stable profitability and revenue, its recent price action suggests potential weakness.  Further analysis is needed to determine if the current undervaluation presents a long-term investment opportunity.

**1. Performance Comparison:**

JNJ's cumulative return is 24.93%, significantly lagging behind the S&P 500's 71.02% return. This results in a considerable divergence of -46.1%, placing it at the 43.2nd percentile of its historical range of performance relative to the S&P 500.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 29.0% | 56.0% | 0.0% | -0.0 | 275.3 |
| 2016-2018  | 9.0% | 10.8% | -8.0% | 0.1 | 261.2 |
| 2017-2019  | 19.0% | 10.8% | -10.0% | 0.7 | 303.6 |
| 2018-2020  | 15.0% | 10.8% | -14.0% | 0.5 | 336.4 |
| 2019-2021  | 33.0% | 7.9% | -41.0% | 0.4 | 374.9 |
| 2020-2022  | 10.0% | 59.9% | -10.0% | 0.3 | 397.3 |
| 2021-2023  | -22.0% | 60.6% | -50.0% | 0.5 | 363.2 |
| 2022-2024  | -36.0% | 60.6% | -52.0% | 0.4 | 345.7 |
| 2023-2025  | -4.0% | 79.7% | -7.0% | 0.3 | 369.3 |


The data shows inconsistent alpha values (ranging from -8% to 0.7%), suggesting periods of both outperformance and underperformance relative to the market.  The beta generally hovers around 0.3-0.7, indicating moderate sensitivity to market movements.


**2. Recent Price Action:**

* **Closing Price:** $153.24
* **5-day Moving Average:** $157.50
* **20-day Moving Average:** $161.97
* **60-day Moving Average:** $156.68

The price is below all three moving averages, suggesting a bearish trend.  The recent price drop of -$4.12 (from $159.82) indicates a short-term downturn.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4693 (High Risk)
* **RSI:** 36.84 (Oversold territory, but not necessarily a strong buy signal)
* **PPO:** -0.81 (Bearish signal)
* **Recent Relative Strength Change:** +14.0 (Short-term upward movement, but insignificant given overall trend)
* **Expected Return:** -53.5% (This extremely negative figure requires further investigation and context.  It's likely an error or based on unrealistic assumptions.)

The technical indicators paint a bearish picture, with high risk and negative momentum signals.  The significant negative expected return needs clarification.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-23 | $1.12  | $22.47B      |
| 2024-07-25 | $1.95  | $22.45B      |
| 2024-05-01 | $1.35  | $21.38B      |
| 2024-02-16 | $1.68  | $21.39B      |
| 2023-10-27 | $10.32 | $21.35B      |

EPS shows significant volatility, and there's a large discrepancy between the October 2023 EPS ($10.32) and subsequent quarters.  Further investigation is needed to understand this unusual fluctuation.  Revenue remains relatively stable.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |
| 2024-03-31 | $21.38B    | 69.55%        |
| 2023-12-31 | $21.39B    | 68.23%        |

Revenue is relatively stable, with high and consistent profit margins.

**Capital and Profitability:**

| Quarter | Equity      | ROE   |
|---------|-------------|-------|
| 2024-12-31 | $71.49B    | 4.80% |
| 2024-09-30 | $70.16B    | 3.84% |
| 2024-06-30 | $71.54B    | 6.55% |
| 2024-03-31 | $70.02B    | 4.65% |
| 2023-12-31 | $68.77B    | 5.89% |

Equity and ROE show some fluctuation but remain relatively stable.


**6. Overall Analysis:**

JNJ's fundamental financial health appears sound, with consistent revenue and high profit margins. However, its recent stock performance lags significantly behind the market, indicated by negative alpha, and supported by negative technical indicators and current price action below moving averages.  The unusual EPS in October 2023 needs to be investigated. The extremely negative expected return (-53.5%) is concerning and requires further examination to determine its validity.  A long-term investment decision would require further due diligence, addressing the inconsistencies highlighted in the data and clarifying the unexpectedly low expected return.  The current undervaluation relative to the S&P 500 might present an opportunity, but the risks should be carefully considered.
